Efficacy and safety of transcatheter arterial infusion chemotherapy with gemcitabine and nab-paclitaxel regimen for advanced pancreatic cancer
10.3969/j.issn.1008-794X.2024.05.009
- VernacularTitle:吉西他滨联合白蛋白结合型紫杉醇经导管动脉灌注治疗晚期胰腺癌的疗效及安全性
- Author:
Zhewei ZHANG
1
,
2
;
Hui ZENG
;
Jiaping ZHENG
;
Jun LUO
;
Liwen GUO
;
Fei CAO
;
Weiren LIANG
;
Guoliang SHAO
Author Information
1. 310022 浙江杭州 浙江省肿瘤医院介入治疗科
2. 中国科学院杭州医学研究所
- Keywords:
gemcitabine;
nab-paclitaxel;
arterial infusion chemotherapy;
advanced pancreatic cancer
- From:
Journal of Interventional Radiology
2024;33(5):512-515
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of transcatheter arterial infusion with gemcitabine and nab-paclitaxel(GN)as first-line therapy in treating patients with advanced pancreatic cancer.Methods The clinical data of a total of 50 patients with advanced pancreatic cancer,who were treated with transcatheter arterial infusion chemotherapy with GN regimen at the Zhejiang Cancer Hospital of China between January 2016 and December2020,were collected The objective effective rate(ORR),progression-free survival(PFS),overall survival(OS)and treatment-related toxic reactions were analyzed.Results A total of 236 times of transcatheter arterial infusion chemotherapy were carried out in the 50 patients,with an average perfusion procedure of 4.72 times per patient.Complete remission(CR)was obtained in 0 patient,partial remission(PR)in 16 patients,and stable disease(SD)in 21 patients.The ORR was 32％,the median PFSwas5.1 months,and the OS was 9.8 months.The main adverse events included neutropenia,thrombocytopenia,vomiting,nausea,fatigue,etc.Conclusion For patients with advanced pancreatic cancer,transcatheter arterial infusion chemotherapy with GN regimen carries good short-term efficacy and safety,it can improve patient's PFS and OS to a certain extent.(J Intervent Radiol,2024,33:512-515)
